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In the 1970s, Stella Chess found a high prevalence of autism in children with congenital 
rubella syndrome (CRS), 200 times that of the general population at the time. Many 
researchers quote this fact to add proof to the current theory that maternal infection 
with immune system activation in pregnancy leads to autism in the offspring. This rubella 
and autism association is presented with the notion that rubella has been eliminated in 
today’s world. CRS cases are no longer typically seen; yet, autistic children often share 
findings of CRS including deafness, congenital heart defects, and to a lesser extent 
visual changes. Autistic children commonly have hyperactivity and spasticity, as do CRS 
children. Both autistic and CRS individuals may develop type 1 diabetes as young adults. 
Neuropathology of CRS infants may reveal cerebral vasculitis with narrowed lumens and 
cerebral necrosis. Neuroradiological findings of children with CRS show calcifications, 
periventricular leukomalacia, and dilated perivascular spaces. Neuroradiology of autism 
has also demonstrated hyperintensities, leukomalacia, and prominent perivascular 
spaces. PET studies of autistic individuals exhibit decreased perfusion to areas of the 
brain similarly affected by rubella. In both autism and CRS, certain changes in the brain 
have implicated the immune system. Several children with autism lack antibodies to 
rubella, as do children with CRS. These numerous similarities increase the probability 
of an association between rubella virus and autism. Rubella and autism cross many 
ethnicities in many countries. Contrary to current belief, rubella has not been eradicated 
and globally affects up to 5% of pregnant women. Susceptibility continues as vaccines 
are not given worldwide and are not fully protective. Rubella might still cause autism, 
even in vaccinated populations.
Keywords: rubella, congenital rubella syndrome, autism, congenital rubella infection, rubella virus, autistic 
spectrum
introdUCtion
Rubella “is so mild and its sequelae so severe that any connection between them would hardly be 
suspected … it put so much distance between itself and its sequelae – at least several months and 
into the next generation – that it was not detected until epidemiological overconfidence from a long 
period of quietly getting away with it” (Aycock and Ingalls, 1946). Diligently following the evidence, 
rubella is likely still “getting away with it.”
After widespread vaccination, the congenital rubella syndrome (CRS) babies almost disappeared 
from the developed world. Currently less than a handful (usually <2) of cases of CRS occur in 
the US each year (Dobson, 2014). The US is a widely covered population with regards to rubella 
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vaccination. But perhaps those few straggling cases of CRS each 
year are just the tip of the iceberg. Maybe rubella does not always 
cause a full-blown case of CRS easily recognized as it did in the 
1960s. Maybe there is a lesser-known outcome: a disorder widely 
diagnosed today, autism.
Autism has many known causes; yet, even in aggregate 
these known causes only account for a minority of cases. The 
majority of autistic cases are idiopathic. Among the known 
genetic and epigenetic causes of autism, rubella has long been 
overlooked. Autistic children often share findings of CRS. 
Neuropathology and neuroradiology findings in autism often 
hint at a viral etiology. The rubella virus, like autism, crosses 
many ethnicities in many countries. In some well-developed 
regions of the world, immigrants from less-developed areas 
have more children affected by autism, leading to theories 
of exposure. Contrary to current belief, rubella has not 
been eradicated and globally affects up to 5% of pregnant 
women – as detected only by serology, not clinically. Without 
serological studies of pregnant women, rubella’s presence 
would not be known. Vaccination is essential, but some women 
do not seem to respond to the vaccine, and titers can wane 
over time, leaving older mothers more at risk. Susceptibility 
continues as vaccines are not given worldwide and are not fully 
protective. Rubella might still cause autism, even in vaccinated 
populations.
rUBeLLa and aUtisM
In the 1960s–1970s, Stella Chess likened autism in children 
with CRS to “a chronic infection in which recovery, chronicity, 
improvement, worsening, and delayed appearance of the autistic 
spectrum all were found” (Chess, 1977). She studied a group of 
243 children with CRS, ages 2.5–3 years old, and using Kanner’s 
strict criteria diagnosed autism in 10, and partial autism in 8 of 
them. Diagnosing a total of 18 children affected with autism in 
the 243 children with CRS, she quoted a prevalence of 7.41%, a 
prevalence over 200 times that of the general population of the 
US at that time (Chess, 1971). In a follow-up study of 205 of the 
original children at the ages of 8–9 years old, including 17 of the 
initial 18 with autism, she then diagnosed an additional 4 cases. 
In this follow-up study, her incidence of autism was (17 + 4)/205 
or 10.24% (Chess, 1977) using the guidelines of the 1970s to 
diagnose autism; if she had used the current guidelines, she likely 
would have diagnosed a greater percentage. While Chess studied 
the outcome of the 1963–1964 rubella epidemic in New York, two 
other groups in Houston and Philadelphia likewise followed CRS 
affected infants.
Desmond and others in Houston reported neurologic symp-
toms in 81 of 100 CRS cases. At birth, nervous system symptoms 
included: bulging fontanelle (45%), lethargy (28%), irritability 
(45%), head retraction, back arching (49%), problems with tone 
(81%), difficulties swallowing (15%), and convulsions (27%). At 
18 months, the surviving group of 64, had neuromotor problems 
(50%), hyperactivity (25%), stereotyped postures and movements 
(18.8%), delayed or absent language (75%), autism (12.5%), and 
hearing loss (45.3%) (Desmond et al., 1969). In reference to theses 
case series, Stella Chess concluded, “the high prevalence of autism 
was one consequence of the invasion of the central nervous sys-
tem by the rubella virus” (Chess, 1977).
In Philadelphia, Lindquist, Plotkin, and peers estimated 
approximately 1–1.4% of all births had been affected by rubella 
during the 1960s outbreaks (Lindquist et  al., 1965), the largest 
outbreaks in US history. In 1964–1965 alone, the US saw an 
estimated 12.5 million cases of rubella, resulting in 2000 cases 
of encephalitis (or 1 in 6250 cases), 11,250 abortions, 2100 cases 
of neonatal deaths, and 20,000 cases of CRS. Of the 20,000 cases 
of CRS: 11,000 (55%) were deaf, 3580 (17.9%) were blind, and 
1800 (9%) were mentally retarded (Jacobson et al., 2009). During 
these largest outbreaks in US history, the association of rubella 
and autism became apparent, but only through massive numbers 
of known infected individuals. The strongest argument against 
a spurious association is the fact the children studied with CRS 
had prevalence rates of autism over 200 times that of the overall 
prevalence rate of autism at that time, the 1970s. In 2015, with 
widespread vaccination in the US, for rubella to remain a causa-
tive factor in autism, unknown infected individuals must exist.
rUBeLLa teratoGeniCity
In the 1940s, an Australian ophthalmologist, Norman M. Gregg 
was the first to suggest rubella as a teratogen of congenital cata-
racts (Gregg, 1991). His theory was not immediately accepted, 
but soon became evident as the epidemic spread with the global 
movement of people during World War II. The 1940s established 
rubella embryopathy, beginning with the classic triad of cataracts, 
deafness, and heart defects recall (Dunn, 2007).
Rubella contains a single-stranded RNA (9762  nt), a nucle-
ocapsid, a lipoprotein envelope, and spiky projections E1 and 
E2. E1 is the major epitope (Lee and Bowden, 2000; Bantavala 
and Brown, 2004). Humans are the only natural host; the human 
host receptor is unknown (Webster, 1998; Lee and Bowden, 2000; 
Nguyen et  al., 2013). Once rubella invades a cell, an inclusion 
body (50–70  nm) develops in the cytoplasm. These inclusions 
appear to be virus-modified lysosomes, which are often linked to 
mitochondria and endoplasmic reticula. Rubella utilizes energy 
from the mitochondria, and incorporates cardiolipin from the 
inner lining of the mitochondria into rubella virions (Lee and 
Bowden, 2000). Rubella’s use of cellular organelles likely stunts 
cellular growth. In vitro studies show stagnant cell division. 
Rubella slowly replicates causing little apoptosis and a steady 
presence (Lee and Bowden, 2000). Rubella also induces much 
larger cytoplasmic inclusions in the 5–8  μm range identified 
as “macrolysosomes” (Kouri et  al., 1974). Rubella disrupts the 
cytoskeleton of cells by depolymerizing actin (Lee and Bowden, 
2000), a molecule necessary for mitosis, signaling, and migration; 
without actin, cells cannot easily divide or position themselves for 
proper embryonic development.
A mother infected with rubella develops viremia in 5–7 days, 
and possibly a rash at 16–20 days, though 50–75% of cases are 
without known exposure and without symptoms, or are sub-
clinical (Webster, 1998; Lee and Bowden, 2000; Dobson, 2014). 
Congenital rubella infection (CRI) is viremia spread to the fetus, 
but does not designate whether the fetus has defects of CRS 
(Dobson, 2014). The highest chance of fetal infection occurs if a 
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mother is infected with rubella at <12 weeks or >36 weeks gesta-
tion, with a range of 25–100% throughout pregnancy (Webster, 
1998). Fetal infection (CRI) can be chronic and often persists after 
birth; babies can have prolonged shedding of virus for up to a 
year after birth, but rarely up to and past 2 years (Dobson, 2014). 
This persistent shedding aids the rubella contagion. Concerning 
CRS or defects, Miller et al. studied clinically diagnosed rubella 
virus exposure at various gestational ages and found that 100% 
of fetuses infected <11 weeks gestation had defects of CRS; 35% 
of fetuses 13–16 weeks had defects (deafness), and 0% of fetuses 
after 16  weeks had defects (Miller et  al., 1982). Pregnancies 
with rubella infections clinically diagnosed in the second and 
third trimesters had a higher percentage of intrauterine growth 
restriction, but otherwise the babies did not have defects at 
birth (Dobson, 2014). The placenta was often small, resulting in 
placental insufficiency with fetal intrauterine growth restriction 
in 25% (Webster, 1998; Lee and Bowden, 2000) and birth weights 
<2500 g in 23% of cases with CRI (Dobson, 2014). Data on CRI 
and CRS reflect 1960s–1970s studies consisting of rubella infec-
tion in pregnancy of never-vaccinated non-immune hosts, with 
clinically apparent cases. Much of this data have not been updated 
in the past 40–50 years.
How exactly rubella induces birth defects is not entirely 
known, but certain factors suggest probable mechanisms. 
Rubella infects the placenta through its vasculature and then 
may infect any part of the fetus. In the placenta, pathology of 
aborted early gestations shows necrotic foci, and later gestations 
shows more vasculitic and inflammatory changes (Webster, 
1998). Subsequent to vasculitis, rubella spreads to other tissues 
both directly though disrupted vascular lumens, and indirectly 
through emboli of infected cells and circulating infected mono-
nuclear cells (Webster, 1998; Nguyen et al., 2013). Rubella does 
not infect all fetal cells, but sporadically infects about 1 in 1000 
to 1 in 100,000 cells; and then continues to exist within that cell’s 
progeny (Webster, 1998; Lee and Bowden, 2000). In this manner, 
rubella may evade the immune system. Using immunofluores-
cence, pathology has shown infected organs have scattered foci 
of infected cells, compact and with discrete borders (Webster, 
1998; Lee and Bowden, 2000). In vitro, human astrocytes are 
“selectively and heavily infected” (Webster, 1998). Because not 
all cells are infected, most cells and structures are grossly normal 
with only foci of abnormal cells and their clones. Hence, rubella 
leads to foci of stunted and displaced tissues (Lee and Bowden, 
2000). Another possible cause of teratogenicity is cell destruction 
caused by inflammatory changes and or autoimmune processes 
(Webster, 1998). These processes occur later and are more notable 
in rubella infections of gestations >20 weeks and after birth (Lee 
and Bowden, 2000).
Crs and rUBeLLa seQUeLae
Because the virus can infect any part of the developing fetus, any 
organ can be affected. The more common anomalies attributed 
to rubella or the “A” findings include: hearing loss, heart defects, 
cataracts, and pigmented retinopathy. The lesser attributed signs 
or “B” findings include: microcephaly, developmental delay, 
hepatosplenomegaly, purpura, jaundice, meningoencephalitis, 
and radiolucent bone disease. CRS is diagnosed with an A finding 
and lab confirmation in the newborn with any of the following: 
serologic rubella-specific IgM, persistent rubella-specific IgG, 
and polymerase chain reaction (PCR) positive for rubella or 
isolated rubella virus. CRI is diagnosed by lab confirmation only. 
CRI signifies infection in utero, but does not imply any syndrome 
or defects. Probable cases of CRS have 2A findings, or 1A and 1B, 
but no lab confirmation. Suspected cases of CRS have B findings 
only (Dobson, 2014; Pitts et al., 2014).
As children develop, behavioral findings associated with CRS 
may emerge and include: hyperactivity, spastic diplegia, absent 
or delayed language, or autism (Desmond et al., 1969; Webster, 
1998). Late changes include diabetes mellitus type 1 (DM1), 
thyroid disorders, and hypertension (Dobson, 2014). After the 
Australian epidemic of rubella in the 1940s, over 40 CRS affected 
individuals were followed >50  years. Concerning DM1, 20% 
developed DM1 by age 25, and 22% by 50–60 years. More recent 
data put the estimate of DM1 in CRS individuals at 1% by adoles-
cence. Thyroid disorders occurred in 5% of survivors (Dobson, 
2014). Theories regarding the late findings include autoantibodies 
confusing rubella and self isotopes (Dobson, 2014), and rubella-
specific immune complexes circulating and causing proteinuria, 
abnormal glucose tests, thyroiditis, and seizures (Coyle et  al., 
1982). Another late, but rare finding in CRS is progressive rubella 
panencephalitis (PRP), a slow and often fatal inflammatory brain 
disorder (Dobson, 2014). Early defects, behavioral changes and 
later complications were all described several decades ago, the 
result of perinatal rubella infections in mothers without any prior 
contact with rubella.
Crs FindinGs oCCUr WitH aUtisM
Congenital rubella syndrome comorbidities: the early effects of 
Gregg’s embryopathy, then behavioral changes and finally late 
consequences are seen in autism. Looking at Gregg’s embryopathy 
or the three most attributed findings with CRS: deafness occurs 
in 60% of CRS cases, heart defects occur in 45% of CRS cases, eye 
findings of cataracts occur in 25% of CRS cases, and pigmented 
retinopathy occurs in 5% of CRS cases (Dobson, 2014). In trying 
to link all of these findings together with autism, there are no 
current studies past the original studies reported from New York, 
Houston, and Philadelphia. Looking at the three areas of hearing, 
heart and vision defects each individually with autism a few good 
studies emerge. Hearing deficits and auditory hypersensitivity are 
common in children with autism. A review article quotes a study 
by Rosenthal et al. diagnosing moderate to severe hearing loss in 
7.9%, and severe hearing loss in 3.5% of a group of 199 children 
with autism; a study by Gillenberg et al. diagnosing hearing loss in 
13.3% of a group with autism; a study by Klin estimating hearing 
abnormalities, both of central and peripheral origin, in 33–46% 
of persons with autism; and a study by Jure demonstrating autism 
in 5.3% of hearing impaired individuals (Hitglou et  al., 2010). 
Regarding congenital heart disease (CHD), a study of children, 
420 with CHD and 108,048 without CHD, showed that the group 
with CHD had more diagnoses of autism; OR 4.6 (95% CI 1.9–11) 
(Razzag et al., 2015). Lastly, visual changes noted with autism do 
February 2016 | Volume 10 | Article 254
Hutton Does Rubella Cause Autism?
Frontiers in Human Neuroscience | www.frontiersin.org
not include cataracts, but include more refractive errors, strabis-
mus, and perceptual differences. Certain studies show an increase 
in strabismus in individuals with autism, ranging from 20 to 50% 
(Simmons et al., 2009). A more recent study investigated ophthal-
mological exams of a group of 324 patients with autistic spectrum 
disorder (ASD) uncovering 22% with refractive errors and 8.6% 
with strabismus (Kabatas et al., 2015). The common features of 
CRS, including hearing loss, heart defects, and visual changes, 
are also seen in autism.
As far as behavioral changes noted with CRS: hyperactivity, 
neuromotor problems, or spastic diplegia, absent or delayed 
language, and autism (Webster, 1998; Dobson, 2014); autism 
is built-in as one of the findings, and delayed speech is a factor 
in the diagnosis of autism. Only hyperactivity, and neuromotor 
problems or spastic diplegia will be investigated for current 
associations with autism. Severe hyperactivity and the diagnosis 
of attention deficit hyperactivity disorder (ADHD) are frequent 
in subjects with autism, applied to 33% of individuals with ASD 
(Carlsson et al., 2013). Spastic diplegia is commonly categorized 
with cerebral palsy (CP). A 2008 study looking at a cross-section 
of 8 years old noted 6.9% of 8 years old with CP had autism; a bit 
paradoxically 18.4% of 8 years old in the non-spastic CP group 
had autism (Christensen et al., 2014). A 1997 study noted CP in 
2.9% of children with autism (Fombonne et al., 1997). Behavioral 
changes noted with CRS definitely overlap with autism, and the 
overlay of autism with CP hints at a cerebral insult in the prenatal 
period.
Late manifestations of CRS mainly include endocrinopathies 
such as DM1 and thyroid disorders, but also hypertension and 
vascular disease. Is there any evidence of these diagnoses in 
the autistic population? A 2012 study out of the Boston area 
examined comorbidities in 14,000 hospital patients with autism. 
They stratified their data by ages 0–17 years and 18–34 years to 
see which diagnoses increased with age and found that DM1 
increased from 0.67 to 2.08% (Kohane et al., 2012). Investigating 
endocrinopathies, DM1 increases over time in a small percent-
age of patients with autism. Looking at vascular disease in 
autism, which has been ascribed to CRS, a study of 108 ASD 
patients followed into adulthood found 34.9% to be obese, 
31.5% to have hyperlipidemia, and 19.4% to have hypertension. 
The only one of these findings significantly above the control 
cohort was hyperlipidemia with an OR of 2.0 (Tyler et al., 2011). 
Hypertension, though seemingly common in persons with 
autism, is not particularly increased above the general popula-
tion. Late diagnoses seen in a small percentage of individuals 
with CRS are merely hinted at in autism, as though autism might 
be a diminutive form CRS.
Lastly does PRP, a declining neurological disorder with 
symptoms typically of dementia, ataxia and/or seizures (Kuroda 
and Matsui, 1997), have any correlation to autism? For the true 
diagnosis of PRP, the answer is clearly no. However, autism has 
a regressive or sometimes called disintegrative form in which a 
normally developing child will regress, often losing language and 
motor skills, and/or having seizures. In autism, epilepsy ranges 
from 19 to 33% with some subclinical cases only picked up by 
EEG, and with a higher percentage of epilepsy existing in the dis-
integrative/regressive form of autism (Muhle et al., 2004; Kohane 
et al., 2012). Regressive autism shares symptoms with PRP, but 
unlike PRP is not often described as fatal. Once again autism, the 
disintegrative form for this comparison, is perhaps just a wisp of 
the full outcome of CRS, in this case PRP.
neUropatHoLoGy in rUBeLLa and 
aUtisM
In these next paragraphs, first CRS will be examined for neuro-
pathology findings and then autism will be similarly examined 
for neuropathology findings. A few points: neuropathology from 
CRS cases is often from aborted fetuses after a prenatal diagnosis. 
As there is no prenatal diagnosis for autism, there are no such 
studies available for comparison. Furthermore, neuropathology 
cases of CRS mostly come from severe, fatal cases in infancy. 
Neuropathology cases of autism are less prevalent; and as autism 
is not often fatal, the specimens are not from severe cases, but 
rather from incidental deaths in adulthood at ages extending 
beyond 60 years old.
Neuropathology of CRS is often studied on specimens elec-
tively aborted after a prenatal diagnosis. CRS findings are consist-
ent with viral invasion and replication within the brain, but of 
few cells overall, not all cells (Webster, 1998). Cerebral vascular 
lesions and hemorrhages occur in early embryos infected with 
rubella (Webster, 1998). Of 67 aborted fetuses with CRS, no 
gross abnormalities were seen, but 68% had microscopic changes 
and 32% had no microscopic changes. Some chorionic cells had 
eosinophilic cytoplasmic inclusion bodies (Tondury and Smith, 
1966). In 2015, a study from Vietnam of three aborted fetuses 
with CRS, showed no encephalitis, but rubella RNA was detected 
by PCR in the fetal CNS (Nguyen et al., 2013). As CRS is esti-
mated to infect 1 in 1000 to 1 in 100,000 cells of the fetus, in some 
pathology specimens minimal changes are seen (Webster, 1998).
Neuropathological studies of children severely affected with 
fatal cases of CRS often show extensive changes. Rourke studied 
the brains of nine infants <1 year of age and noted leptomeninges 
with fulminant degeneration (Rorke and Spiro, 1967). Pathology 
of youths approximately ages 8–20 who died after PRP demon-
strated significant volume loss with white matter destruction, 
vasculitis, cerebellar atrophy, fulminant necrosis, and old infarcts. 
Theories on the cause often include inflammatory insults, cerebral 
vasculitis, and to a lesser extent direct viral inhibition of growth 
and destruction of cells (Kuroda and Matsui, 1997; Webster, 1998; 
Sawlani et al., 2013).
The other major finding in CRS neuropathology is that of cer-
ebral necrosis, often in the periventricular areas. Rourke reported 
necrotic foci in deep white matter and gray nuclei (Rorke and Spiro, 
1967). Rubella often follows vascular routes causing ischemia 
along their distributions, especially the small penetrating vessels 
(Webster, 1998). Emboli of necrotic cells in brain arterioles and 
desquamation of vessel lumens were visualized (Tondury and 
Smith, 1966). Cerebral blood vessels show focal areas of destruc-
tion with thickened walls and narrowed lumens (Webster, 1998). 
Pathology suggests the virus causes vasculitis and cellular emboli. 
Although many infants died of cyanotic cardiac lesions which 
might also result in emboli, the vasculitis and cerebral emboli 
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are attributed to the rubella virus because similar vascular lesions 
are seen in some embryonic brains from first trimester abortions 
(Webster, 1998). In summary, the neuropathology of CRI/CRS 
cases may reveal no abnormalities as seen in some embryonic 
cases; or may show degenerative changes, cerebellar atrophy, 
infarction (especially periventricular), and cerebral vasculitis 
with narrowed lumens.
Looking at autism, neuropathology studies are infrequent and 
incidental. Though brains from CRS cases and from autism share 
the similarity of many normal appearing brains, there are many 
dissimilarities. Instead of degeneration and neuronal loss as seen 
in CRS, studies of autism suggest increased brain growth, espe-
cially in the forebrain, in the first 1–2 years of life with 20–25% of 
children with autism having macrocephaly (Wegiel et al., 2010; 
McFadden and Minshew, 2013). In the frontal lobe, neurons appear 
smaller and more densely packed, with abnormal organization of 
the minicolumn, a vertical unit of cortex organization (Acosta 
and Pearl, 2003; Wegiel et  al., 2010; Williams and Casanova, 
2011; McFadden and Minshew, 2013). Poor differentiation is 
often seen at the white-gray matter junction (especially in the 
periventricular area) thought to be due to excess remnant cells. 
Autistic brains’ growth has been studied from infancy well into 
adulthood. In CRS, most brains are studied only from neonates 
to infants. In autism, abnormal neuronal connections have been 
implicated and mapped with newer high definition fiber track-
ing technology aided by improved functional imaging. Though 
widely speculated, increased shorter connections and decreased 
longer connections in autistic brains have been both proven and 
unproven (Sundaram et al., 2008; Williams and Casanova, 2011; 
McFadden and Minshew, 2013). Decreased pruning of synapses 
is evidenced and accepted by most (Williams and Casanova, 2011; 
McFadden and Minshew, 2013). Some brains show temporal 
horn dilation, and cells in the temporal area have been shown to 
have an abundance of dendritic spine densities (McFadden and 
Minshew, 2013). Many studies show decreased Purkinje cells in 
the cerebellum, thought to generate, migrate and die before birth 
with inflammatory microglial cell activation (Tondury and Smith, 
1966; Bailey et al., 1998; Acosta and Pearl, 2003; Whitney et al., 
2009; Williams and Casanova, 2011; McFadden and Minshew, 
2013). The prenatal loss of Purkinje cells in the cerebella of those 
with autism unlikely correlates with cerebellar atrophy seen in 
those with PRP, as cerebellar atrophy would seemingly result 
from an overwhelming inflammatory attack of the brain well 
after birth. Both suggest inflammation, but in general, studies of 
brains from autistic subjects do not show infarction or vasculitis. 
CRS demonstrates more ischemic and degenerative changes, and 
autism elucidates more changes in growth and connectivity.
Autistic brains also have their own findings of ectopic brain 
tissue and one case with cellular inclusion bodies. In a case series 
of six brains, of a 4-year old five individuals in their 20s, with 
more severe cases of autism (Bailey et al., 1998), some interest-
ing findings emerge with possible links to CRS or perhaps other 
heterogeneous causes of autism. The brains weighed more 
than average brains of like aged children, but the brain stems 
and cerebella weighed less. Findings of one or more children 
showed hyperconvoluted temporal lobes, blurred white-gray 
matter areas, ectopic gray matter, ectopic neurons in cerebella 
and lateral to the olives, inferior olive malformations, and 
decreased Purkinje cells in cerebella. One child had cytoplasmic 
eosinophilic inclusions in cerebellar Purkinje cells of about 
7 μm and staining deeply with Luxol fast blue and cresyl violet. 
Cytoplasmic inclusions frequently signify a viral infection, but 
the authors only pondered the inclusions hinted at the varied 
causes of autism (Bailey et al., 1998). Another case series of 13 
brains from autistic individuals of ages ranging from 4 to 60 years 
showed subcortical- periventricular, hippocampal and cerebellar 
heterotopias in 4 of 13; cerebellar dysplasia in 4 of 13; cerebellar 
malformation in 5 of 13; and floculonodular cerebellar dysplasia 
in 6 of 13. They theorized problems in maturation and migration 
and pointed to genes related to migration and cytoarchitecture 
(Wegiel et  al., 2010). Thinking back to rubella’s infection of 
sporadic cells and their clones, rubella’s scattered foci of infected 
cells, and rubella’s ability to depolymerize actin – a molecule with 
functions in cell shape, motility, signaling, mitosis, junctions and 
migration of cells in embryogenesis (Webster, 1998; Lee and 
Bowden, 2000) – could explain findings in the autistic brain of 
heterotopic foci of immature neurons, aberrant connections, and 
the loss of Purkinje and temporal lobe cells (Figure S1). Not to 
overlook the many dissimilarities in neuropathology studies of 
CRS and autism, but one wonders what adult brain specimens 
of mildly affected CRI/CRS might show neuropathologicaly with 
newer fiber tracking technology.
neUroiMaGinG in rUBeLLa and 
aUtisM
Neuroimaging of CRS individuals includes adolescents and adults, 
and surprisingly their scans have similarities to neuroimaging 
of autistic individuals; neuroradiology studies of CRS are less 
common as more prevalent CRS cases existed before magnetic 
resonance imaging (MRI) or positron emission tomography 
(PET) came into existence, and also neuroradiology studies of 
autistic children probably have a bias toward higher functioning 
individuals who can tolerate such imaging, or rather, being in the 
machines with loud noises while able to follow commands. MRI 
was not available during the larger epidemics of rubella in the 
developed world, but there are a few case series and case stud-
ies of brain MRI results in CRS survivors. A case series by Lane 
et al. imaged brains of 11 CRS affected individuals and showed 
white matter hyperintensities in 6 of the 11 studied. White matter 
lesions, associated foci of ischemic necrosis, and small associated 
cysts showed involvement of penetrating vessels in the deep 
white matter and represented ischemic brain damage along the 
path of vessels affected by the rubella virus. Periventricular areas 
and basal ganglia were frequently involved (Lane et  al., 1996). 
There are several case reports of neurological MRI findings in 
CRS children. An MRI of a case documented in 2013 showed 
cystic encephalomalacia, periventricular calcifications, atrophic 
changes in the temporal lobe, and lesions consistent with gliosis 
and demyelination (Sawlani et al., 2013). Another case from 2013 
showed “diffuse leukoencephalopathy with subcortical anterior 
temporal cysts, which showed spontaneous improvement during 
a period of 3 years” (Severino et al., 2014). A suspected case of 
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CRS documented in 2014, in a boy also diagnosed with autism, 
showed cystic encephalomalacia in “the subcortical white matter 
of the left posterior temporo-parietal occipital lobes and left basal 
ganglia” (Hutton and Hutton, 2014). A computed tomographic 
(CT) scan of a case published in 2008 showed calcifications in 
the left corona radiata (Pitts et al., 2014). MRI and CT of a CRS 
case from 2003 showed calcifications in the periventricular area 
and basal ganglia (Numazaki and Fujikawa, 2003). A CT scan of 
a case of CRS in 2000 showed microcephaly, periventricular leu-
komalacia, calcifications, and subcortical atrophy (Bullens et al., 
2000). To summarize, brain MRI findings of CRS affected indi-
viduals often show white matter hyperintensities, calcifications, 
leukomalacia, and atrophic changes, in areas described along the 
distribution of deep penetrating vessels at the white-gray matter 
junction, periventricular areas, temporal areas, and basal ganglia.
Magnetic resonance imaging and PET scan studies of indi-
viduals with autism are numerous and largely have a bias toward 
higher functioning individuals. Repeating a case listed above, and 
serving as a reminder of findings, a suspected case of CRS in a 
boy also diagnosed with autism showed encephalomalacia espe-
cially in the temporal area and basal ganglia, and also prominent 
perivascular spaces (Hutton and Hutton, 2014). A study from 
France of 69 ASD children showed 52% (36 of 69) had normal 
MRIs, and 48% (33 of 69) showed findings of: abnormal white 
matter signals (19 of 69), dilated Virchow–Robin/perivascular 
spaces (12 of 96), and temporal lobe abnormalities (20 of 69). 
The authors even state that the white matter hyperintensities 
found in the posterior horns of the lateral ventricles were similar 
to those of “periventricular leukomalacia, metabolic disorders, 
viral infections or vascular disorders”; white matter abnormalities 
have been seen in CP; and that some deep white matter lesions 
(area of deep penetrating vessels) cause suspicion for “a vascular 
etiology.” They further theorized that the temporal lobe changes 
could explain epilepsy seen in many individuals with ASD. They 
concluded that findings were non-specific overall, but white mat-
ter hyperintensities and temporal lobe abnormalities were seen in 
26% of their cases (Boddaert et al., 2009). Of all the studies, this 
one reports MRI findings very similar to those seen with CRS, 
most notably the hyperintensities seen in white matter suggestive 
of viral or ischemic changes, and temporal horn abnormalities. 
Another French study of 77 children with autism, showed loss of 
gray matter in the superior temporal sulcus in 21 cases, and PET 
scans showed decreased blood flow in the same region (Brunelle 
et al., 2009; Zilbovicius et al., 2013). Many PET scans of autistic 
brains show decreased flow in cerebral vessels, a finding akin to 
rubella affected brains. PET scans on 15 children with autism and 
infantile spasms showed 13 had decreased metabolic activity in 
the temporal lobe, 9 in the frontal lobe, and 7 in the parietal lobe 
(Dilber et  al., 2013). A PET study on autistic subjects showed 
decreased perfusion in the temporal cortex, insula, mediofrontal 
cortex, left inferior frontal cortex, and left middle frontal cortex. 
No areas had increased perfusion (Ohnishi et al., 2000). In another 
PET study from Japan, 22 individuals with ASD had decreased 
blood flow to bilateral latero-temporal and dorso-medio-lateral 
frontal areas; the left side being worse than the right (Hashimoto 
et al., 2000). Diffusion tensor imaging studies also reveal changes 
in the frontal, temporal, and parietal lobes (Sundaram et  al., 
2008; Ke et al., 2009). In theory, areas with decreased perfusion 
are linked to increased hypoxia and lower intelligence (Sharma 
et al., 2013; Zilbovicius et al., 2013). Referring back to MRIs of 
individuals affected by CRS, many show periventricular leu-
komalacia and calcifications suggestive of end-artery occlusion, 
and atrophic changes in the temporal area of the brain. There are 
no PET studies of children with CRS, yet areas in the brain with 
less perfusion and metabolic activity seen in autistic persons cor-
relate to areas affected by CRS. Pathology of CRS cases typically 
demonstrates that rubella causes vasculitis, narrowed lumens 
and brain ischemia at the deep penetrating arteries of the brain 
(Webster, 1998). Possibly, then the PET studies of autistic indi-
viduals demonstrating decreased perfusion with brain hypoxia 
could be a result of these vessel changes and or ischemic changes 
caused by rubella virus (Figure S1).
neUroiMMUnoLoGy in Cri and 
aUtistiC indiVidUaLs
Growing evidence in the field of neuroimmunology points to an 
immune mechanism in the cause of autism, either innate with 
chronic activation, a maternal response which attacks the fetal 
brain, or perhaps an autoimmune reaction. Lab techniques and 
serology tests have progressed in the last 40 years, so that immune 
studies are more advanced and encompassing with regards to 
autism. Embryos with CRI, and CRS infants, pathologically show 
more cerebral vasculitis than encephalitis. However, neurological 
aspects also implicate immune system involvement especially in 
later gestations (past 20 weeks) (Lee and Bowden, 2000), in CRI 
cases with encephalitis sometimes lasting for years, and in PRP 
(Webster, 1998). Though early embryos rarely show evidence of 
inflammation, those after 20  weeks often show increased IgM, 
IgG, IgA, natural killer cells, T cells, and interferon (Lee and 
Bowden, 2000). A case of a boy who died from PRP showed 
increased IgA and IgG specific to rubella in the brain as opposed 
to sera. IgA was increased 1- to 60-fold, particularly in the pari-
etal lobe and cerebellum; and IgG was increased 8- to 27-fold, 
particularly in the parietal and temporal lobes. The authors 
postulated the immunoglobulins were produced in the brain to 
bind up antigen, and hence these were the areas most affected 
by the virus (Wolinsky et  al., 1982). CRS is often described as 
a persistent infection in infancy (Dobson, 2014; Bantavala and 
Brown, 2004). Autism is described as a persistent immune reac-
tion, most notably in the frontal and temporal lobes (Michel et al., 
2012). Evidence of inflammation in brains includes the chronic 
activation of microglial cells is seen in both autism (Goldani 
et  al., 2014) and CRS (Lindquist et  al., 1965). In considering 
immune modulators, many tests for cytokines were not avail-
able 30–50 years ago when more children were diagnosed and 
studied with CRS; information as such is minimal, though alpha-
interferon (INF-alpha) was shown to be increased in fetuses with 
CRI (Lee and Bowden, 2000). With autism, multiple studies 
show increased inflammatory cytokines in the sera of those with 
autism. Such inflammatory cytokines include: interleukin-1beta, 
interleukin-6, interleukin-8, tumor necrosis factor alpha (TNF-
alpha), and gamma-interferon (INF-gamma); and with many of 
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these cytokines, the higher their concentrations, the more severe 
are the symptoms of autism (Ashwood et al., 2011; Michel et al., 
2012; Xu et al., 2015). On the other hand, the anti-inflammatory 
cytokine transforming growth factor-beta is decreased in persons 
with autism (Michel et al., 2012). TNF-alpha is postulated to have 
an effect on pruning of synapses within the brain (Michel et al., 
2012). Recent data on cytokines and rubella infection are lacking, 
especially in vivo studies. An in vitro study “interrogated” 33,000 
genes before and after infecting human cells of fetal and adult 
lines with rubella, demonstrating upregulation and downregula-
tion in 632 and 516 genes, respectively of multiple modalities: 
inflammation; cell growth, division, structure, adhesion, and 
signaling; and unknown functions (Adamo et al., 2008). Again 
in CRS, given the era of in depth investigations, INF-alpha is the 
only documented immune modulator known to be increased. 
Investigating inflammatory markers in CRI needs much advance-
ment, with the aforementioned article being a good start.
Maternal infection has been implicated in autism. In a study 
of possible vertically transmitted viruses in the brains of subjects 
with autism, the 15 autistic brain specimens had more PCR evi-
dence of BK virus, JC virus and simian virus 40 combined than 
the 13 control brain specimens (Lintas et al., 2010). They did not 
include rubella virus in their search. Women with anti-influenza 
antibodies in the first half of their gestation have a three to seven 
times increase of having a child with autism (Shi et  al., 2009). 
Pregnant mice given influenza mid-gestation had offspring with 
decreased Purkinje cells in the cerebella, heterotopic Purkinje 
cells, and delayed migration of neurons. The same outcome 
happened if the pregnant mice were given dsRNA poly(1:C), an 
immune stimulant (Shi et al., 2009). More recently, similar find-
ings are emerging in a rhesus monkey model (Weir et al., 2015). 
Unfortunately, there is no current animal model for CRI. In 1967, 
a study demonstrated teratogenicity of rubella in macaques and 
baboons (Wilson and Gavan, 1967). An animal model might 
help elucidate further pathophysiology, but animal models have 
not been developed. CRS brain lesions may result from mater-
nal inflammation (Shi et al., 2009), and CRS is associated with 
autism, and was before the diagnosis of autism became expansive 
and common. In groups of children with CRS, 7.41–12% also 
had autism (Desmond et al., 1969; Chess, 1971, 1977); the 7.41% 
estimate was 200 times the prevalence of autism in the general 
population in the 1970s.
GenetiCs oF aUtisM and rUBeLLa 
iMMUnity
For years, scientists studying autism have searched for an under-
lying genetic pathway. Genetics was strongly implied by a twin 
study showing 60% of monozygotic (MZ) twins were concordant 
for autism while 0% of dizygotic (DZ) twins were concordant 
for autism. When expanded to look at the broader spectrum of 
autism, 92% of MZ twins and 10% of DZ twins were concordant 
(Bailey et  al., 1995; Muhle et  al., 2004). Genetic studies began 
screening families with members affected by autism, families 
with de novo cases of autism, and a slew of genes with any pos-
sible relation to autism. These paths have been quite divergent, 
investigating over 500 different genes, with several genetic loci 
on every chromosome (Goldani et al., 2014). More recent studies 
estimate environmental factors likely account for at least 58% of 
autism (Michel et al., 2012; Goldani et al., 2014). Many MZ twins 
share placental blood circulation, such that an infection would be 
more likely to affect both MZ twins than DZ twins (Michel et al., 
2012), though there is a case study of CRI in MZ twins where one 
twin escaped rubella infection (Wang et al., 1990). Furthermore, 
genetics do not account for the first-born preponderance, or male 
predominance in autism with the male to female ratio in autism 
being about 4:1. The Boston study cited above, also found the 
typical male to female ratio of 4:1, and looking at genetic disorders 
in their autism population they found 0.5% had Fragile X, 0.8% 
had Tuberous Sclerosis (TS), and 0.9% had Down Syndrome (DS) 
(Kohane et al., 2012). The genetic disorders of fragile X, TS, and 
DS closely mimic an older study by Fombonne in 1997, showing 
of 174 children with autism 2.9% had chromosomal abnormali-
ties including Fragile X, 1.1% had TS, 1.7% had DS, and 0.6% had 
neurofibromatosis (Fombonne et al., 1997). Boys with fragile-X 
and autism led to many gene investigations on the X chromosome. 
Though autism affects a preponderance of males, autism has not 
been found to be X-linked as male to male inheritance occurs 
(Muhle et al., 2004). Possibly unrelated, but notable, all 20 cases of 
PRP described from 1974 to 1997 have been males (Kuroda and 
Matsui, 1997). No one is certain yet why autism affects so many 
more males than females. Genetic studies have not given a good 
explanation, and most known syndromes causing autism such as 
TS and DS only account for a small percentage of the autistic 
spectrum overall.
If 58% of autism is environmental, then what explains the 
estimated 42% which may be genetic. Perhaps the genetic fac-
tor has to do with a susceptibility to rubella. The host receptor 
for rubella has yet to be determined, which might account for 
some variation (Lee and Bowden, 2000). Further, individuals can 
have different responses to the rubella vaccine. A study of twins 
showed that there is considerable heritability to rubella vaccine 
response. The ratio of genetic variance to total variance was 
45.7% (p. 003) (Jacobson et al., 2009). This and similar studies 
linked HLA haplotypes and single-nucleotide polymorphisms to 
changes seen in individual responses to the rubella vaccine with 
regards to immunoglobulin levels, immunoglobulin avidity, and 
production of certain cytokines (Jacobson et al., 2009; Kennedy 
et al., 2014; OvsyannikovaI et al., 2014a,b). Vaccinated women 
reinfected in pregnancy may have a defect of immunity such that 
they do not make effective antibodies. Though they show some 
evidence of immunity, they are actually susceptible (Best et al., 
1989). Consequently, the rubella virus, still circulating the globe, 
with no country completely eradicating the virus, infects non-
immune persons, including those incapable of mounting strong 
immune responses.
LaCK oF rUBeLLa antiBodies in 
indiVidUaLs WitH Crs and aUtisM
Peculiar to CRS survivors is often their lack of immunity to 
rubella. In utero, the fetus has an immature immune system, and 
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if CRI occurs early, then the fetus will not recognize the virus 
as foreign. CRI individuals develop a tolerance to rubella, in 
particular the E1 epitope (Dobson, 2014; Mauracher et al., 1993; 
Hyde et al., 2014). With CRI, IgG to rubella is increased at birth 
and mostly reflects maternal antibody. If months later, IgG to 
rubella continues to be elevated, then the infant has developed 
an immune response to the rubella pathogen; and persistently 
elevated IgG to rubella (before any given vaccination) is one 
possible lab diagnosis of CRI. Interestingly, in 10–20% of CRI 
infants, the rubella-specific IgG will drop to undetectable levels, 
and cannot be stimulated by boosters of rubella vaccine (Dobson, 
2014). This immune tolerance may contribute to viral persistence 
(Webster, 1998; Bantavala and Brown, 2004). Two studies of 
antibodies in children with autism yielded compelling results. 
Of 15 children with ASD, 5 of 13 had undetectable antibodies 
to rubella despite vaccination; in comparison, 8 neurologically 
typical (NT) children all had antibodies (Stubbs, 1976). Another 
study which grouped 33 classic autism children and 26 regressive 
autism children, found 15 of these 59 combined children had low 
or no antibodies to rubella; as opposed to 2 of 49 in the control 
group, a combination of 24 children with Tourettes syndrome and 
25 NT children (Libbey et al., 2007). Yet, in another study of 31 
children with ASD and 29 NT children, the antibodies to rubella 
were similar in both groups (Gentile et  al., 2013). Combining 
these studies, 20 of 103 children with autism lack antibodies to 
rubella, similar in ratio to those with CRS lacking antibodies to 
rubella.
rUBeLLa VaCCine eFFeCtiVeness
With rubella vaccination, a reported 92–98% of individuals will 
respond with adequate antibodies; however, the vaccine is a live 
attenuated virus and must be kept cold (the cold chain). With 
the more usual handling, the response is 86–97% (Jacobson et al., 
2009). Lack of immune response is considered primary vaccine 
failure, and as above ranges from 2 to 8%, or 3 to 14% (with less 
than perfect handling of the vaccine). Secondary failure is when 
an individual becomes infected after having prior immunity. 
In many countries, a second vaccine is given to help overcome 
primary and secondary failures. Concerning rubella vaccination, 
secondary failure is also documented. In Italy, 9.8% of females 
were reinfected within 5  years of vaccination with wild-type 
rubella (Banerji et al., 2005; Jacobson et al., 2009). In a 1990 study 
from California, 43% of congenital rubella occurred in moms who 
had prior rubella vaccinations (Jacobson et al., 2009), about that 
time the US vaccine schedule added a second MMR. Secondary 
failure or reinfection with rubella after vaccination is thought to 
be a rare event, and even rarer to cause a child with CRS, yet there 
are several documented cases. A mother vaccinated 4 years before 
becoming pregnant, with a rubella titer of 1:64, had a child with 
CRS (Miron and On, 1992). A mother vaccinated 7 years prior to 
the birth of her child had a child with CRS (Enders et al., 1984). A 
mother with repeated evidence of immunity had a child with CRS; 
the child had low immunoglobulin levels (Weber et al., 1993). In 
another case, the mother had a rubella IgG titer of 425 IU/ml at 
12 weeks. Initially, this titer was classified as immunity; however, 
after the birth of her child with CRS, the titer was clarified as 
an immune response to rubella infection (Banerji et al., 2005). 
A study evaluating reinfection of mothers giving birth to babies 
with CRS noted that 8 of 16 of the mothers had rubella titers 
>15  IU/ml, and even >25  IU/ml (Bullens et  al., 2000). These 
authors could not suggest a lower titer to fully protect against 
rubella reinfection. Since that study in 2000, several more cases 
of CRI/CRS have been reported, as born to: a woman with an 
anti-rubella titer of >  1:16 (Aboudy et  al., 2000); a physician 
mom with a low-titer early in pregnancy and likely infected at 
work in a hospital with a large immigrant population (Hutton 
and Hutton, 2014); a woman immunized 14 years prior with a 
pre-pregnancy titer of 1:16 and a 9-week titer of 1:512 (Ushida 
et al., 2003); a woman with an early anti-rubella titer interpreted 
as “immune” early in pregnancy (Numazaki and Fujikawa, 2003); 
a woman vaccinated 5  years before the birth of her child with 
a documented anti-rubella titer >400 IU/ml 5 years before her 
pregnancy to which the authors state she must have had a quickly 
waning titer or low avidity antibodies (Pitts et al., 2014); and a 
mother with an early pregnancy anti-rubella titer >15  IU/ml 
and HIA 1:1024 (Sawlani et al., 2013). To summarize these cases 
of reinfection in pregnancy, several occurred after vaccination 
within 4–7  years, with anti-rubella titers >15  IU/ml, and with 
high early pregnancy titers initially thought to reflect immunity, 
but in hindsight reflecting reinfection.
At the first prenatal visit, a rubella titer is drawn, even in those 
having completed vaccination schedules to rubella, so that women 
whose titers have waned can receive booster rubella vaccinations 
(Measles, Mumps Rubella vaccine – MMR) after delivery; thus 
concluding that some women with documented prior vaccination 
are expected to have low titers. How fast do titers drop? Several 
studies have tried to answer this question. In Taiwan, rubella 
vaccination was implemented in 1986. A study checking prenatal 
titers from 2002 to 2008 revealed 6.5% of women had negative 
titers (<10 IU/ml) and 8.7% had low titers (10–20 IU/ml), total-
ing 15.2% with negative or low titers, and with a mean decay rate 
of −0.77 IU/ml per year (Lin et al., 2012). In Finland, children 
vaccinated at 14–18 months and then at 6 years were followed, 
and titers were measured in those vaccinated up to 20  years 
after initial vaccination. Though all had detectable antibodies at 
20 years, 36% had titers <15 IU/ml and 17% had titers <10 IU/
ml. Of Finnish mothers in their early 20s, about a third have low 
levels of antibody to rubella.
Some studies show the possible influx of natural immunity. In 
Finland, of 178 children aged 14–18 months, 1.1% were immune 
to rubella before receiving any rubella vaccine. In Central Europe, 
224 vaccinated adolescents were followed. After the first vaccine, 
92.1% were immune. Titers measured before the second vaccine 
was given showed at three times increase in 7.8% of those with 
low titers <40 IU/ml, suggesting a “secondary immune response.” 
After the second vaccine, 100% were considered immune. An 
annual decay rate of −2.9% was calculated (Kremer et al., 2006). 
In Sweden, the 1973 vaccine schedule included one dose of 
rubella vaccine, and the 1982 schedule included two doses. They 
followed 486 girls up to 16 years after vaccination. At 16 years, 
22% had titers below 1:16 and 6% lacked antibodies, totaling 28%. 
Mean titers in the 1st, 8th, and 16th year after vaccination were 
1:110, 1:34, and 1:18, respectively. At 8 years after vaccination, 
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they found a fourfold rise in 36% of participants, and only in 1% 
of participants in the following 8–16  years, suggesting natural 
immunity occurs more frequently at younger ages (Christenson 
and Bottiger, 1994). Historically, this may not have changed much 
in the US before widespread vaccination, rubella infections were 
most commonly seen in 5–9 years old (Lee and Bowden, 2000). 
In the Netherlands, after following rubella immunity for 32 years, 
they concluded that titers decrease more quickly after one vaccine 
than two vaccines, and higher antibody titers are maintained in 
individuals following natural infections (Smits et  al., 2014). 
Natural infection with rubella produces higher antibody levels, by 
5–10 times, than vaccination (Kremerrr and Muller, 2005). There 
is no worldwide consensus on what titer constitutes rubella non-
immunity. Those countries using enzyme-linked immune assays 
(ELISA) use cut-offs of <10 or <15 IU/ml or sometimes <20 IU/
ml; those countries using hemagglutin inhibition assays (HIA) 
use cut-offs of <1:8 or <1:16. How do ELISA and HIA relate? 
One article states 1:8 HIA correlates to 15 IU/ml (Robinson et al., 
2006); and in another 1:16 HIA correlates to 15 IU/ml (Bullens 
et al., 2000).
In addition to reinfection being documented by incidental 
titers or vaccinated mothers giving birth to children with CRS, 
reinfection has also been documented by a study directly reinfect-
ing those with prior immunity and by a study during an epidemic. 
Of 29 volunteers with prior vaccination to rubella, reinfected 
nasally with rubella virus, 6 of 29 (20.69%) were reinfected as 
diagnosed by a four times increase in titer. No level of anti-rubella 
titer was found to be protective. A comparison group also with 
prior vaccination to rubella was challenged intranasally with 
vaccine-attenuated virus, and none of those exposed showed evi-
dence of reinfection or increased titers (Harcourt et al., 1980). A 
military study followed 190 men exposed to rubella virus during 
an epidemic. Of 26 men never exposed or vaccinated, all became 
infected. Of 15 men with prior vaccination, 12 (80%) showed 
serology consistent with reinfection. And of 149 men with prior 
natural immunity, only 5 (3.4%) were reinfected. Not one rein-
fected individual showed symptoms; of those susceptible, only 
one in three of those infected showed symptoms, demonstrating 
the majority of cases were unnoticeable (Horstmann et al., 1970). 
Subclinical infections are more common in individuals with prior 
vaccine-induced immunity as opposed to those naïve of prior 
immunity, and those with natural immunity resist reinfection 
better than those with vaccine-induced immunity.
GLoBaL Variations in rUBeLLa 
iMMUnity
What is the rate of rubella immunity in the world? Natural immu-
nity worldwide is estimated at 80–85% (Bantavala and Brown, 
2004; Plotkin, 2006). With wide vaccine coverage, areas of Europe, 
Australia, and Turkey estimate 85–90% of their populations are 
immune (Madi et al., 2014). Not differentiating natural immunity 
versus vaccine induced, global immunity to rubella ranges from 
95% in Kuwait, 77.5% in Russia, 76% in Sri Lanka, 71.1% in 
Vietnam, 54.1% in Nigeria to 40% in Panama (Jacobson et  al., 
2009; Madi et  al., 2014; Miyakawa et  al., 2014). More recently, 
Kuwait estimates only 88.4% of their population is immune. Of 
the 11.6% who are non-immune, 4% are Kuwaiti citizens with 
wide vaccine coverage, and 7.6% are immigrant workers with 
inconsistent vaccine coverage (Madi et al., 2014). In addition to 
waning titers and the influx of unvaccinated immigrants, rubella 
non-immunity may be increasing due to those concerned about 
MMR vaccines causing autism opting for their children not to be 
vaccinated. In the UK, a surveillance study has shown the rate of 
rubella non-immunity increasing from 4.1 to 6.8% over 5 years 
(Mortlock and Farthing, 2014). The rate of autism in the UK is 1 
in 102 (Shuman, 2014). In Japan, vaccine gaps have occurred with 
regards to measles, mumps, and rubella. Of those who opted out 
of vaccination, 12.4% are non-immune to rubella (Okuda et al., 
2008). Japan has had recent rubella outbreaks with the outbreak 
in 2012–2013 causing 40 cases of CRS as of March 2014 (Ohkusa 
et  al., 2014; Saitoh and Okabe, 2014). Of pregnant women in 
Japan, 1.1% test positive for rubella-specific IgM (Okuda et al., 
2008). Incidentally, the rate of autism in Japan is one of the high-
est in the world, 1 in 55 (Shuman, 2014).
Waning titers are common in populations with vaccine sched-
ules to rubella, but what happens in populations without such 
vaccine schedules? In Vietnam, a prospective surveillance study 
done in 2014 diagnosed 113 cases of CRS, giving a rate of 1.13 per 
1000 births in Hanoi (VanBang et al., 2014). A similar 2014 study 
conducted in Nha Trang, Vietnam, found a CRI rate of 1.51/1000 
live births, and that older moms were more likely to have natural 
immunity (Miyakawa et al., 2014). A 2014 paper from Tanzania, 
where rubella vaccines are not scheduled, estimated natural 
immunity in pregnant women at 92.6%. In older women, ages 
25–44 years, 94% had natural immunity. In younger women, ages 
15–24  years, 89% had natural immunity. The authors estimate 
natural immunity increases each year by 12%, and that the high 
natural rate of immunity suggests ongoing endemic transmission. 
They also tested pregnant women for rubella-specific IgM and 
found 0.3% to be positive in Tanzania (Mwambe et al., 2014). In 
the developing world, older moms have more natural immunity. 
Contrasting what occurs in the developed world with more vac-
cine coverage, older moms have less immunity due to the decay 
of titers over time.
perinataL risKs oF aUtisM and Crs, 
WitH FoCUs on tHe ForeiGn Born 
MotHer
Many studies have looked at perinatal risk factors for autism; 
common among these risks are: prematurity, low APGARs, 
low or high birth weight, advanced maternal and paternal ages 
(AMA, APA), certain medicine exposures, vaginal bleeding in 
pregnancy, gestational diabetes, breech presentation, hyper-
bilirubinemia in the newborn, first born child, and foreign born 
mothers – especially if born in East Asia and Sub-Saharan Africa. 
One meta-analysis of such studies published in 2009, determined 
that AMA, APA, certain medicines, vaginal bleeding in preg-
nancy, gestational diabetes, and first born child all met statistical 
significance for risk factors of autism. Mother born abroad had 
an increase of 28% with a p-value of 0.006 (Gardener et al., 2009). 
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Another meta-analysis published in 2012, found that AMA, APA, 
first born child, medicines, foreign born mother, small for ges-
tational age, hyperbilirubinemia, breech presentation, preterm 
delivery, and low APGARs all met significance for risk factors 
of autistic spectrum, including pervasive developmental disorder 
(Guinchat et al., 2012). Sweden has commonly cited that foreign 
born mothers have an increased risk of having a child with autism, 
with East Asian moms having an OR of 3.4, and Sub-Saharan 
African mothers having an OR of 7.3 (Haglund and Kallen, 2011). 
Further Swedish studies have shown that Somali born mothers 
had a three to four times higher risk of having children with 
autism in 1988–1999, and then this increased to a four to five 
times higher risk in 1999–2003. In the latter estimate, the risk of a 
Somali woman giving birth to a child with autism was 0.98 versus 
0.21% in a group not of Somali background. Also >80% of autistic 
children born to Somali women had “profound hyperactivity” 
(Barnevik-Olsson et al., 2010). The Swedes have also calculated 
that 15% of children born to mothers from Uganda had autism, 
200 times that of their general population (Gillberg et al., 1995). 
How could these risk factors fit with CRI? Elevated bilirubin and 
low birth weight are lesser signs seen with CRS/CRI. APA and 
AMA correlate with waning immunity or increased susceptibil-
ity to rubella in developed countries. First born children may be 
more affected because once a mother becomes naturally immune, 
she better resists subsequent infection. Foreign born mothers 
(from the developing world, without vaccinations) are less likely 
to be immune or again more likely to be susceptible to rubella.
Similar to cases of autism, many cases of CRS in developed 
nations are born to women originally from areas without rubella 
vaccination programs, especially Sub-Saharan Africa, Asia and 
South America (Bantavala and Brown, 2004; Banerji et al., 2005). 
In the US, from 2004 to 2012, five of six cases of CRS occurred 
in children born to mothers either originating from or having 
recently traveled to Tanzania, Nigeria, Sudan, Ivory Coast, and 
Asia (with travel to India, China, and Singapore) (Jacobson et al., 
2009; CDC, 2013). In Australia, from 2004 to 2013, of five cases 
of CRS, all five of the children’s mothers were born overseas, 
including Indonesia, India, Nepal, and Thailand (Khandaker 
et al., 2014).
tHe GLoBaL CirCULation oF rUBeLLa
Developed nations are not the only countries to see imported 
rubella. Rubella cases increase in areas of greater population den-
sity, and different strains circulate with the increased international 
movement of people (Plotkin, 2006; Yoshikura, 2014). In Tunisia, 
all known outbreaks of rubella prior to 2011 had been of a strain 
indigenous to Africa, but during the 2011–2012 outbreak, an 
imported strain was isolated in several Tunisian cases. With this 
outbreak, there was a large incidence of neurological symptoms, 
with 39 of the 280 confirmed cases having encephalitis (Messedi 
et al., 2014). Certain circulating strains today might have more 
neurotropism. From 2007 to 2011, Taiwan has been following five 
rubella strains of imported “clusters,” from Vietnam, Malaysia, 
Thailand, Germany, and South Africa (Cheng et  al., 2013). In 
Brazil, they have recently isolated four genotypes of rubella 
(Curti et al., 2013). In Europe rubella cases are on the rise with 
29,601 cases in 2012, and 39,367 cases in 2013. They estimate 
an increase in 10,000 cases per year, claiming much of the cases 
occur in Poland (Muscat et  al., 2014). In Poland, a 2011–2012 
study states that only 0.2% of cases are diagnosed by serology, and 
99.8% are clinically diagnosed. If 50–75% of cases are subclinical, 
then estimates of rubella cases are assuredly too low (Rogalska, 
2014). As cities are more populated than ever, and people trot 
the globe at ever increasing paces, rubella thrives. Rubella has 
global distribution and will be impossible to eliminate without 
extensive, repetitive, and improved vaccination on a global scale.
aUtisM and VaCCination
If rubella is a current cause of autism, then why does autism exist 
in vaccinated populations? As stated previously, vaccination does 
not prevent reinfection. Primary failures occur when the rubella 
vaccine fails to elicit protective antibodies. Secondary failures 
also occur, when persons with immunity to rubella are reinfected. 
Possibly some of autism is what CRS has become today; CRS with 
less morbidity and mortality at birth, but more development of 
behavioral and neurological effects. If rubella infects 1 in 1000 
to 1 in 100,000 cells in the fetus of a rubella naïve individual 
(Webster, 1998), perhaps it infects an even lesser ratio in an 
individual with incomplete rubella immunity. Inflammation in 
the latter individual would build quickly enough to limit viral 
spread. Rubella is much more likely to come in contact with a 
partially immune host today than decades ago when CRS was 
first described.
Proponents who claim that the MMR vaccine causes autism 
have forced studies to compare the prevalence of autism in 
vaccinated and unvaccinated populations. Studies looking at 
vaccinated versus unvaccinated populations might be expected to 
show a decreased prevalence of autism in vaccinated groups, but 
unfortunately vaccinated and unvaccinated groups do not equate 
with immunity and non-immunity to rubella. In reality, vac-
cinated groups have an estimated 86–97% immunity (Jacobson 
et al., 2009), and unvaccinated groups have an estimated 80–85% 
natural immunity (Plotkin, 2006; Nguyen et al., 2013). To blur the 
picture a bit more, those with natural immunity resist reinfection 
with rubella better than those with vaccine-induced immunity. 
Even if rubella causes autism, these studies may not find much 
difference between the two groups. Further, the aim of these 
studies is not to see if rubella causes autism, but to see if the 
MMR vaccine causes autism. Overwhelmingly, they show that 
the MMR vaccine does not cause autism as there is no statisti-
cally significant increase in diagnoses of autism in the vaccinated 
group. In fact most studies, including a meta-analysis and a large 
Danish population study, show less diagnoses of autism in the 
vaccinated groups. The large meta-analysis involved five cohorts 
consisting of >1.2 million children, showing a decreased odds 
ratio of 0.84 for autism in the MMR vaccination group (Taylor 
et al., 2014). The Danish population study of 537,303 children, 
440,665 receiving MMR vaccination, had a decreased relative 
ratio of 0.92 for autism and 0.83 for ASD (Madsen et al., 2002). 
In Japan, the MMR vaccine was withdrawn in 1992, and a sub-
stantial increase of autism was seen, rising “dramatically,” with the 
birth cohort of 1993. Japan’s incidence of autism increased from 
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approximately 0.6% in 1992 to 1.6% in 1994 (Honda et al., 2005). 
Withdrawing the MMR vaccine did not decrease the incidence 
of autism, but may have inadvertently increased the incidence 
of autism, perhaps by increasing the susceptibility to rubella. In 
Poland, an interesting case-control study of 96 individuals with 
autism and 192 matched controls without autism showed that 
autism in the MMR group versus the unvaccinated group had 
an OR of 0.17; autism in the measles only vaccine group versus 
the unvaccinated group had an OR of 0.44; and autism in the 
MMR group versus the measles only vaccine group had an OR 
of 0.47 (Mrozek-Budzyn et al., 2010). Though small, this study 
suggests that a non-measles component of the MMR vaccine 
might be associated with less autism. Other MMR studies do not 
stratify a measles only vaccine arm. In summary, studies of MMR 
vaccinated and non-vaccinated groups do not show an increase 
of autism in their vaccinated arms, and most trend a decrease in 
the vaccinated arms.
Crs and Cri today
If rubella is a cause of autism, then why is autism so prevalent, 
but CRS is not? First rubella likely causes a certain, yet to be 
determined, percentage of autism, but not all autism. Second, 
rubella can cause spontaneous abortions, and prenatal diagnoses 
of rubella can lead to elective abortions. In the 1964 rubella 
epidemic, there were 20,000 cases of CRS and 11,250 abortions, 
though these abortions are not further classified as spontaneous 
or elective (Jacobson et  al., 2009). The paper by Miller, who 
followed 1000 mothers with documented rubella infections in 
various stages of pregnancy, states that pregnancy continued in 
40% of women; terminations (mostly induced) occurred in 60% 
(Miller et  al., 1982). More recently (1992) in Pakistan, of 350 
pregnancies, rubella-specific IgM was positive in 5% of the 143 
mothers who carried to a live birth, and positive in 18% of the 
212 mothers who naturally aborted. They speculated that rubella 
is a significant cause of miscarriage in Pakistan (Ahmed, 1992). A 
2014 review surveyed 31 studies from developed countries, each 
study reporting outcomes of at least 30 maternal rubella infec-
tions. This review of almost 100 prenatal cases of CRI from 1999 
to 2005 showed that prenatal diagnoses in the developed world 
often led to elective terminations (Thompson et al., 2014). A third 
reason CRS infants are not common has to do with reporting. In 
South Korea, three cases of CRS were reported to the government 
from 2001 to 2009 (9 years), but investigating insurance claims, 
76 cases of CRS were reported to insurance companies from 2005 
to 2009 (5 years) (Choe et al., 2010). In a region of Italy, no cases 
of CRS were reported to the regional government, but pulling 
hospital records revealed one case of CRS, two laboratory con-
firmed cases of CRI, four suspected cases of CRI, and seven cases 
of rubella in pregnancy (Cozza et al., 2015). In 2006, the WHO 
estimated at least 100,000 cases of CRS worldwide (Robinson 
et al., 2006); this can only be estimated as most cases occur in 
areas with little reporting, but even in areas with reporting, cases 
are frequently not counted.
Given the WHO estimate of 100,000 cases of CRS in the world; 
what might then be the incidence of CRI? Or rather how many 
pregnancies are affected by rubella? Worldwide this estimate is 
hard to guess. If only clinically diagnosed cases are considered, 
then 66–75% of CRI cases will be missed and lack follow-up. 
After the 1964 rubella epidemic in the US, a prospective study 
followed 4005 pregnancies with CRI, 68% of the CRI infants were 
asymptomatic at birth; but following these seemingly normal 
children, 71% developed manifestations (mostly hearing loss and 
intellectual disabilities) by 5  years of age (Dobson, 2014). That 
was 50 years ago; what about data today? There is no reason to 
check umbilical cord blood for rubella as was done in the 60s and 
70s, and babies born with to mothers with prior vaccinations and 
subclinical rubella infections, likely will not teem with blueberry 
muffin spots. Still, a few studies have measured rubella-specific 
IgM in pregnant mothers, finding 5% positive in Pakistan (Ahmed, 
1992), 1.1% positive in Japan (Okuda et al., 2008), 0.3% positive 
in Tanzania (Mwambe et al., 2014), estimating that rubella affects 
somewhere between 0 and 5% of pregnancies globally. A recent 
study from Nigeria tested 300 pregnant women for rubella-specific 
IgG, finding 53% positive for IgG. Only those 53% positive for 
IgG were further tested for IgM, finding 10% positive for rubella-
specific IgM. The percentage of the initial group positive for IgM 
is unknown as only those positive for IgG were tested for IgM, 
but is at least 5.3% (Onakewhor and Chiwuzie, 2011). In the US, a 
study in Houston, of 298 women who tested rubella non-immune 
early in pregnancy, 19 naturally converted to immune at the time 
of delivery by at least a fourfold increase in titer; 6.38% of women 
initially non-immune to rubella became immune to rubella over 
a range of just 10–36 weeks. None of the women had any known 
exposures or symptoms (Hutton et  al., 2014). The title of the 
Houston paper hints at a reemergence of rubella, but more likely 
the study confirms rubella’s persistence. In these last five papers 
(Ahmed, 1992; Okuda et  al., 2008; Onakewhor and Chiwuzie, 
2011; Hutton et  al., 2014; Mwambe et  al., 2014), only serology 
estimated the prevalence of rubella, without serology, doubtfully 
any presence of rubella would be known. Rubella is still “quietly 
getting away with it,” but to what extent can only be guessed.
What is the true burden of CRI? Is it autism? And if so, how 
much autism is caused by rubella virus? An older, frequently 
quoted study by Fombonne revealed 0.6% of a group of 174 
autistic individuals also had a diagnosis of CRS (Fombonne et al., 
1997). Another study, using Chess’s initial prevalence of 7.4%, an 
average birth rate of 4,150,000 per year for the years 2001–2010 in 
the US, and a pre-vaccination rate of CRS of 4/10,000, calculated 
(by multiplying 0.074, the birth rate and 4/10,000) 1228 cases of 
autism were prevented each year in the US from 2001 to 2010 
by vaccination to rubella (Berger et al., 2011). But this estimate 
assumes that there are no current CRI/CRS cases in the US, and 
that MMR vaccination is 100% effective. The thought that vac-
cination has wiped out rubella is falsely reassuring and has man-
aged to wipe out most rubella research, but unfortunately rubella 
lingers. In summary, these estimates are probably too exclusive, 
missing the subclinical CRI in vaccinated mothers with immune 
systems partially primed to mount an inflammatory response 
with cascading changes in the fetal brain. Other facts to consider 
are the increasing rubella cases with circulation from continent 
to continent, the continual rubella susceptibility as vaccines are 
not given globally and are not fully protective, and the exposure 
of rubella in 0–5% of pregnancies worldwide. But of pregnancies 
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affected by rubella, how many offspring have autism? Is it consist-
ent with the estimates of Chess and Desmond in the 60s–70s: 7.41 
(Chess, 1971), 10.24 (Chess, 1977), or 12.5% (Desmond et  al., 
1969); or is it much higher now that the diagnosis of autism has 
expanded to be so much more inclusive?
ConCLUsion
Rubella, once widespread and widely studied 30–50  years ago, 
was linked to autism. Chess proposed that CRS children have 200 
times the prevalence of autism at a time when the diagnosis of 
autism was much more limited. Although rubella is one of many 
maternal infections with possible links to autism, no other infec-
tion boasts such an increased prevalence; perhaps it is time to give 
rubella another look. Autism shares some overlap with the three 
most common findings in babies with CRS: deafness, CHD, and 
to a lesser extent visual changes. Both CRS children and autistic 
children can have hyperactivity, spasticity, and may develop DM1 
as young adults. Neuropathology and neuroradiology of children 
with both CRS and ASD often show brains, which are normal or 
with hints of a faint viral signature of periventricular calcifica-
tions and deep white matter or temporal lobe changes; this pos-
sibly owing to rubella’s sporadic nature, infecting infrequent foci 
of cells and inhibiting their mitosis, maturation, migration, and 
connections. Rubella affects brain arterioles leading to decreased 
perfusion in certain areas of the brain. PET scans of children with 
autism show decreased perfusion in similar areas of the brain. In 
both CRS and autism, changes in the brain implicate the immune 
system. These findings parallel each other even though the bulk of 
CRS research is from 40 years ago, and the bulk of autism research 
is from the past decade. CRS children lack antibodies to rubella 
in 10–20% of cases, as do autistic children. Trying to map out the 
genetics of autism has been quite divergent, though one converg-
ing theory could be a host susceptibility to rubella regardless of 
vaccination. This susceptibility to rubella helps to explain rubella’s 
persistence, even in widely vaccinated populations. Genetics 
does not explain why in certain areas of the world both CRS and 
autistic cases are seemingly imported, or why rubella and autism 
cross many ethnicities with a global distribution. Though rubella 
research has diminished in the last 20  years, current evidence 
linking autism to rubella still exists.
GoinG ForWard
Research must develop to see if rubella plays a role in today’s cases 
of autism. If such studies demonstrated the continued existence of 
rubella, further studies, steps, and measures would be necessary 
to protect mothers and infants.
Possible studies might include
• As in the Houston study listed above, of mothers who convert 
from non-immune early in pregnancy to immune at the end 
of pregnancy (Hutton et  al., 2014), their resulting children 
could be followed for development of autism and or behavioral 
outcomes.
• Pregnant women presenting with flu, cold, or viral symptoms 
could be tested for rubella.
• The Finnish study found 1.1% of children had evidence of 
rubella immunity before ever receiving MMR (Davidkin et al., 
2008). Children could be similarly checked for rubella immu-
nity before vaccination, and those demonstrating natural 
immunity could be monitored for development of autism. One 
caveat would be that certain children exposed in utero might 
not make antibodies.
• Stored umbilical cord blood could be tested for rubella.
• Blinded radiologists could read MRI and PET studies of 
known cases of CRI and autism for inter-rater and intra-rater 
reliability.
• Children with regressive autism could be evaluated for any 
evidence of rubella infection.
• Brain pathology specimens from autistic individuals could 
be investigated for rubella, especially in areas of heterotopic 
tissue.
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